- Home
- IAUX vs DMAC Comparison
IAUX vs DMAC Comparison
Compare IAUX & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- DMAC
- Stock Information
- Founded
- IAUX 2020
- DMAC 2000
- Country
- IAUX United States
- DMAC United States
- Employees
- IAUX N/A
- DMAC N/A
- Industry
- IAUX
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- DMAC Health Care
- Exchange
- IAUX Nasdaq
- DMAC Nasdaq
- Market Cap
- IAUX 261.9M
- DMAC 274.1M
- IPO Year
- IAUX N/A
- DMAC N/A
- Fundamental
- Price
- IAUX $0.51
- DMAC $4.82
- Analyst Decision
- IAUX
- DMAC Strong Buy
- Analyst Count
- IAUX 0
- DMAC 3
- Target Price
- IAUX N/A
- DMAC $7.00
- AVG Volume (30 Days)
- IAUX 7.2M
- DMAC 118.6K
- Earning Date
- IAUX 11-12-2024
- DMAC 11-13-2024
- Dividend Yield
- IAUX N/A
- DMAC N/A
- EPS Growth
- IAUX N/A
- DMAC N/A
- EPS
- IAUX N/A
- DMAC N/A
- Revenue
- IAUX $52,944,000.00
- DMAC N/A
- Revenue This Year
- IAUX N/A
- DMAC N/A
- Revenue Next Year
- IAUX $158.96
- DMAC N/A
- P/E Ratio
- IAUX N/A
- DMAC N/A
- Revenue Growth
- IAUX 30.02
- DMAC N/A
- 52 Week Low
- IAUX $0.34
- DMAC $2.14
- 52 Week High
- IAUX $1.88
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- IAUX 34.03
- DMAC 47.28
- Support Level
- IAUX $0.48
- DMAC $5.05
- Resistance Level
- IAUX $0.66
- DMAC $5.74
- Average True Range (ATR)
- IAUX 0.04
- DMAC 0.37
- MACD
- IAUX 0.00
- DMAC -0.08
- Stochastic Oscillator
- IAUX 6.42
- DMAC 28.10
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.